Rituximab possible treatment option for patients with primary biliary cirrhosis
Friday, February 3, 2012 - 12:31
in Health & Medicine
An open-label study of rituximab, a monoclonal antibody for human CD20, was shown to be safe in patients with primary biliary cirrhosis who had an incomplete response to the standard ursodeoxycholic acid therapy. Rituximab was successful in reducing the level of alkaline phosphatase -- a protein used to measure liver injury, according to the new study.